[{"id":"428cac7f-133f-43b4-8121-71893e06b7fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498912","created_at":"2021-01-18T12:03:05.635Z","updated_at":"2025-02-25T14:35:42.787Z","phase":"Phase 1","brief_title":"Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors","source_id_and_acronym":"NCT02498912","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" MUC16 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • JCAR020 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-31"}]